news, journals and articles from all over the world.
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
Cedars-Sinai Cancer is advancing its commitment to diversity in research by participating in the largest-ever national study of cancer risk factors in Asian Americans. Investigators are hoping to learn why Asian Americans have disproportionately high rates of many types of cancer.
Houston Methodist researchers have developed an advanced mathematical model that predicts how novel treatment combinations could significantly extend progression-free survival for patients with non-small-cell lung cancer (NSCLC), the most common type of lung cancer.
A new way of diagnosing lung cancer with a blood draw is 10 times faster and 14 times more sensitive than earlier methods, according to University of Michigan researchers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
People with limited-stage small cell lung cancer may benefit from adding immunotherapy to chemoradiation, but not if both treatments are given at the same time, new research finds.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features compelling data on lung cancer advances presented by MD Anderson researchers at the 2024 World Conference on Lung Cancer.
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
MSK researchers have identified two signaling pathways that work together to spur the spread of lung cancer. Taking away one of those signals could help slow or stop metastasis, findings in animal models suggest.
The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast.
Cleveland Clinic expert is available to discuss research published in Cancer Discovery. According to the American Cancer Society, lung cancer is the number-one cancer killer of both men and women in the United States, accounting for over 125,000 deaths per…
When it comes to cancer disparities, community may count. A new study in the Journal of the National Cancer Institute showed that although Hispanic non-small cell lung cancer patients tend to be diagnosed at later stages than White patients, that disadvantage disappears in South Florida.
The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.”
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Invenio Imaging, a leader in intraoperative fresh tissue imaging and artificial intelligence (AI), announced today the enrollment of the first patients in a US pivotal study of its AI-based image analysis module for lung cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Ochsner Medical Center – Baton Rouge now offers robotic-assisted bronchoscopy using the Ion robotic platform, a new, minimally invasive option for lung biopsy.
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more precise intensity-modulated radiotherapy (IMRT) over the alternative 3D-conformal radiotherapy (3D-CRT) for patients with unresectable, locally advanced non-small cell lung cancer (NSCLC).
As many as 70% of smokers looking to quit say they enlist the help of e-cigarettes or vaping devices to kick the habit – according to a recent study. Because the devices allow you to control the strength of nicotine,…
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
New study shows UC Davis total-body advanced PET scanner EXPLORER can visualize dual blood supply in lungs and effectively evaluate lung cancer and track treatment progress.
A new study led by American Cancer Society researchers shows less than one-in-five eligible individuals in the United States were up-to-date with recommended lung cancer screening. The screening uptake was much lower in persons without health insurance or usual source of care and in Southern states with the highest lung cancer burden.
In recognition of her work breaking down language barriers around the world by creating Spanish-language educational content about lung cancer for patients and caregivers, Sylvester Comprehensive Cancer Center’s Dr. Estelamari Rodriguez has been honored as GRACE Patient Educator of the Year.
Korean joint research team have elucidated the overexpression of estrogen signaling pathways in specific Korean never-smoking lung cancer cases using multi-omics analysis and proposed the anti-cancer drug saracatinib as a targeted therapeutic agent.
Exposure to increased neighborhood violence has the power to change the glucocorticoid receptor (GR) for the stress hormone, cortisol, which may influence the aggressiveness of lung cancer, according to data presented Sunday at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Mass.
A new study that examined the cost-effectiveness of durvalumab, a targeted immunotherapy for lung cancer, could help guide drug-pricing strategies to reduce financial burdens and increase the number of patients who benefit from treatment.
Background: KRAS mutant NSCLC remains a therapeutic challenge. Although KRAS G12C inhibitors are now approved for cases harboring that specific mutation, their efficacy is modest and the G12C variant accounts for only 40% of KRAS mutations in NSCLC. To date,…
Background: Brain metastasis (BM) represents a significant clinical challenge in the management of lung cancer, impacting patient prognosis and treatment decisions. While various predictive models have been developed to assess the risk of BM development, their performance and applicability remain under…
Available for interview on breaking news, trending topics in respiratory medicine
Former cigarette smokers who use e-cigarettes or vaping devices may be at higher risk for lung cancer than those who don’t vape, according to research published at the ATS 2024 International Conference.
For up to 30% of patients who are allergic to medical contrast dye or have a dye restriction because of other health conditions, they might find that it takes longer to get a diagnosis when it comes to life-threatening lung issues such as pulmonary embolism.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
A research team from Tufts University School of Medicine and Massachusetts General Hospital is now reporting evidence that hillocks and their stem cells are physiologically distinct from other cells within the lung and consist of a stratified outer layer of scale-like squamous cells that protect an underlying layer of rapidly expanding basal stem cells that are capable of restoring airway tissue after injury.
Mickey Allen was 89 years old when she was diagnosed with Stage 3B lung cancer. How did her age impact her treatment options? University of Chicago Medicine oncologists explain what factors they consider when creating treatment plans for patients in their 80s and 90s.
New study by UC Davis researchers shows how pharmacies may provide crucial access to tobacco cessation tools that help people successfully quit smoking.
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
With only a small percentage of Marylanders at high risk for lung cancer getting the recommended annual screening, the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) today launched a new statewide effort to increase annual screenings.
Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.
A Medicare policy requiring primary care providers (PCPs) to share in the decision-making with patients on whether to proceed with lung cancer screening is fraught with confusion and lack of evidence-based information, and may actually be undermining the purpose for which it was created, Mount Sinai researchers say.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.
Recent NCCN Guidelines updates—along with the supporting evidence—will be presented during the NCCN 2024 Annual Conference held in Orlando, Florida April 5-7, and simultaneously online. Visit NCCN.org/conference to learn more and register.
The lungs are one of the most difficult organs for physicians to navigate with a conventional bronchoscope. To overcome these limitations, a team of NIH-funded researchers built a compact robotic system that can autonomously steer a flexible needle around these anatomical obstacles within the lungs of live animals.
Researchers at The University of Texas MD Anderson Cancer Center built a new atlas of lung cells, uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung cancer. These findings, published today in Nature, open the door for development of new strategies to detect or intercept the disease in its earliest stages.
A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).
Radon is the second leading cause of lung cancer. Now a new study has found exposure to this invisible, odorless gas is also linked to an increased risk of stroke.
In patients who undergo pulmonary resection for lung cancer, a major potential postoperative complication is venous thromboembolism (VTE)—a condition that develops when a blood clot forms in a vein—which can lead to part of the clot breaking off and lodging in the lung, resulting in a pulmonary embolism (PE).
A new pathologic scoring system that accurately assesses how much lung tumor is left after a patient receives presurgical cancer treatments can be used to predict survival, according to new research led by investigators at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center and the Mark Foundation Center for Advanced Genomics and Imaging at the Johns Hopkins University.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu